Falguni Nayar of Nykaa is 2nd richest, with net worth of ₹57,520 cr; she’s also India's richest self-made woman, shows 'Leading Wealthy Women 2021' report by Hurun India, Kotak Private Banking
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
The 68-year-old Biocon chairperson retorted that information related to overseas entities were disclosed to regulatory agencies, and Kunal Kashyap's role is devoid of any legal authority.
Biocon's executive chairperson Dr Kiran Mazumdar Shaw, calls for a PLI scheme specially focused on incentivising biopharma investment.
The executive chairperson of Biocon exhorts the government to revisit pharma price controls from a global perspective, in order to incentivise local manufacturing in the industry.
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
